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2Abstract
Human immunodeficiency virus type 1 protease (HIV-1 PR) is one of the
proteins that currently available anti-HIV-1 drugs target. Inhibitors of HIV-1 PR have
become available, and they have lowered the rate of mortality from acquired immune
deficiency syndrome (AIDS) in advanced countries. However, the rate of emergence of
drug-resistant HIV-1 variants is quite high because of their short retroviral life cycle and
their high mutation rate. Serious drug-resistant mutations against HIV-1 PR inhibitors
(PIs) frequently appear at the active site of PR. Exceptionally, some other mutations
such as L90M cause drug resistance, although these appear at non-active sites. The
mechanism of resistance due to non-active site mutations is difficult to explain. In this
study, we carried out computational simulations of L90M PR in complex with each of
three kinds of inhibitors and one typical substrate, and we clarified the mechanism of
resistance. The L90M mutation causes changes in interaction between the side chain
atoms of the 90th residue and the main chain atoms of the 25th residue, and a slight
dislocation of the 25th residue causes rotation of the side chain at the 84th residue. The
rotation of the 84th residue leads to displacement of the inhibitor from the appropriate
binding location, resulting in a collision with the flap or loop region. The difference in
levels of resistance to the three inhibitors has been explained from energetic and
structural viewpoints, which provides the suggestion for promising drugs keeping its
efficacy even for the L90M mutant.
 
3Introduction
Human immunodeficiency virus type 1 (HIV-1) proliferates under the
assistance of its own aspartic protease, so-called HIV-1 protease (PR), in its life cycle1.
HIV-1 PR is an enzyme composed of two identical polypeptides, each of which consists
of 99 amino acid residues (Fig.1A), and has a function to process the viral Gag and
Gag-Pol polyprotein precursors. Because this processing is essential for the viral
maturation, the inhibition of PR function leads to an incomplete viral replication and
prevents the infection of other cells2. Therefore, HIV-1 PR is an attractive target for
anti-HIV-1 drugs. Seven PR inhibitors (PIs) have been approved by the FDA3-9 and
have successfully lowered the death rate due to acquired immune deficiency syndrome
(AIDS) in advanced countries during the past decade. However, the emergence of PI-
resistant mutants has become a serious problem in AIDS therapies10-13. The
accumulation of multi-drug-resistant mutations within HIV-1 PR makes it difficult to
control viral replication in patients. Hence, PIs that maintain drug efficacy even for
drug-resistant mutants are needed.
4Fig.1. A: Structure of HIV-1 PR. Locations of the two catalytic aspartates, the 84th and
the 90th residues, are shown in stick representation. The WT sequence of HIV-1 PR is
shown below. B: Chemical structures of NFV, SQV, LPV and PRRT. Each red dotted
line shows a junction between subsites. The P1 subsite is highlighted with an orange
background, and the P1’ subsite is highlighted with a yellow background.
5Most mutations causing a high level of drug resistance occur at the active site
of HIV-1 PR. For example, D30N and G48V lead to specific resistance against
nelfinavir (NFV) and saquinavir (SQV), respectively, and I84V shows multi-drug
resistance against several approved PIs7, 10-18. Recent structural analyses by not only X-
ray crystallography19-28 but also computational studies29-34 have revealed that these active
site mutations changed direct interactions between PR and PI and caused unfavorable
contact between them. Non-active site mutations such as L10F and L90M have also
been reported to cause a high level of resistance, although these residues cannot directly
interact with PIs7, 10-18. It is difficult to understand how non-active site mutations lead to
resistance against PIs. L90M is a primary mutation responsible for resistance against
NFV and SQV7, 14-17. L90M also appears to be associated with resistance to other PIs11-13.
The structures of L90M PR mutants in complex with PIs have been determined through
X-ray crystallographic approaches by some groups20, 26 and through our previous
computational simulations33. These structures showed that the side chains of the mutated
M90/M90’ altered their interactions with the catalytic aspartates D25/D25’.
Additionally, L90M mutation affected local conformations at the 80’s loop of PR,
which is quite far from the location of the 90th residues. The mechanism of resistance
due to L90M, however, is still not clear, and a strategy for the design of potent drugs
against L90M- acquired virus has not yet been established.
In this study, we carried out computational simulations of L90M PR in
complex with several kinds of ligands to clarify the mechanism of resistance due to
L90M. NFV, SQV and lopinavir (LPV) were selected as representative PI inhibitors
6currently used in the clinical field (Fig.1B). NFV and SQV lose their ability to inhibit
PRs that have acquired L90M mutation. In contrast, single mutations have little effect
on the inhibition ability of LPV35. In addition, the oligopeptide at the PR/RT cleavage
site (PRRT) was selected as a typical substrate for the enzyme to investigate the effect
of L90M on substrate binding (Fig.1B). The PR/RT cleavage site contains Phe-Pro at
the P1-P1’ residues (notation by Schecter and Berger36). It is unusual for mammalian
endopeptidases to cleave the peptide bond located at the N-terminal side of Pro, and this
cleavage site is specific to HIV-1 PR37, 38. This cleavage mechanism is unique as
reported previously39-41. Therefore, the structure of PRRT was used as the base of drug
design for NFV, SQV and some PIs3, 7, 42. In this study, the binding energies of NFV,
SQV, LPV and PRRT were first calculated to compare the levels of resistance of the
wild type (WT) and L90M mutant. The binding structures were then compared in two
groups of inhibitors: one groups consisting of HIV inhibitors that lose drug efficacy due
to L90M mutations, such as NFV and SQV, and the other group consisting of drugs that
maintain efficacy, such as LPV. Prominent differences between the two groups were
seen at the contact of M90 to D25, shifts of D25, rotation of the side chains of I84,
displacement of the flap region of I50, and deformation of the loop region of P81. D25,
I84, I50 and P81 are all located at the active site of the PR. Detail discussion are
developed in contrast with the resistivity of PR. Our findings provide information for
designing better inhibitors that maintain drug efficacy in spite of L90M or other non-
active site mutations.
7Materials and methods
 Molecular dynamics simulation. Before carrying out molecular dynamics (MD)
simulations, quantum chemical calculations were executed for PIs to deduce the atom
charges utilized in MD simulations. Geometry optimization was performed on each PI,
and the electrostatic potential was calculated at the B3LYP/6-31G(d,p) level using the
Gaussian03 program43. The partial atom charges were determined using the RESP
method44 so that the atom charges could reproduce the values of the calculated
electrostatic potential at the surrounding points of the PI. Charges were set equal
between two atoms if they were the same element and had the same bond coordination.
Minimizations and MD simulations were carried out using the Sander module of the
AMBER7 package45. The AMBER ff02 force field46 was used as the parameters for van
der Waals and bonded energy terms basically, and the general AMBER force field47 was
used as the parameters for NFV, SQV, and LPV.
Each initial structure for the clade B HXB2 PRs in complex with NFV, SQV,
and LPV was modeled from the atom coordinates of the X-ray crystal structure (PDB
code: 1OHR48, 1HXB42, 49, and 1MUI50, respectively) using the LEaP module (Fig.1A).
The initial structure for the PR in complex with PRRT before the catalytic reaction was
modeled in the same manner as that previously reported39. The oligopeptide of ACE-
THR-LEU-ASN-PHE-PRO-ILE-SER-NME was utilized as PRRT, and one water
molecule was inserted between PRRT and D25/D25’. Each model was placed in a
rectangular box filled with about 8000 TIP3P water molecules51, with all of the crystal
water molecules remaining. One water molecule was added between LPV and I50/I50’
8in the LPV complex model, because no crystal water molecule was present in the
crystallographic data. It is known that the hydrogen bonds between PI and I50/I50’ via
the water molecule are critically important for PI binding with HIV-1 PR33, 39-41. The
cutoff distance for the long-range electrostatic and the van der Waals energy terms was
set at 12.0 Å. All covalent bonds to hydrogen atoms were constrained using the SHAKE
algorithm52. Periodic boundary conditions were applied to avoid edge effects in all
calculations. Energy minimization was achieved in three steps. At first, movement was
allowed only for the water molecules and ions. Next, the ligand and the mutated
residues were allowed to move in addition to the water molecules and ions. Finally, all
atoms were permitted to move freely. In each step, energy minimization was executed
by the steepest descent method for the first 1000 steps and the conjugated gradient
method for the subsequent 3000 steps. After 52.0 ps heating calculation until 300 K
using the NVT ensemble, 1.5 ns equilibrating calculation was executed at 1 atm and at
300 K using the NPT ensemble, with an integration time step of 1.0 fs. In the present
calculations, the MD simulations showed no large fluctuations after about 500 ps
equilibrating calculation (Supporting Information Fig. S1). Hence, atom coordinates
were collected at the interval of 0.5 ps for the last 500 ps to analyze the structure in
detail.
  Protonation states. The protonation states of catalytic aspartates D25 and D25’ vary
depending on the binding inhibitors or substrates. Hence, the appropriate protonation
states of catalytic aspartates should be determined for the respective ligands. For NFV,
the protonated state was already determined in our previous study33. That is, D25 was
9protonated and D25’ was unprotonated in each of WT PR and L90M PR in complex
with NFV. In order to determine the protonation states when SQV or LPV binds to the
WT PR, the total energies of the two kinds of complexes were compared after energy
minimization. One complex represented a combination of protonated D25 /
unprotonated D25’ states, and the other represented the opposite combination. This
comparison clearly suggested the preference of the protonated D25 and unprotonated
D25’ states (Supporting Information Table S1 A). In contrast to the case of WT PR, we
used another method to determine the protonation states of L90M PR with SQV or LPV
because they might have greatly different conformation from the respective crystal
structures. Hence, we executed 1.5 ns MD simulations of the two protonation states in
these models and compared the total energies of the two protonation states for the last
500 ps of the simulations. The energy comparison indicated that L90M PR in complex
with each of SQV and LPV preferred the protonated D25 and unprotonated D25’ states
(Supporting Information Table S1 B). For both WT and L90M PR with PRRT, the D25
unprotonated and D25’ protonated states were selected so that the hydrolysis reaction
could proceed as described in a previous paper39.
  Binding energy calculation (MM/PBSA). The binding free energy53 was calculated
by the following equation:
?Gb = ?GMM +?Gsol - T?S,
where ?Gb  is the binding free energy in solution, ?GMM is the molecular mechanics
(MM) interaction energy, ?Gsol  is the solvation energy, and ?T?S  is the contribution
of conformational entropy to the binding. Since the contribution of conformational
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entropy to the change of ?Gb  is negligible among the mutants as pointed out by
Massova54, the last entropy term in the energy estimation was neglected. ?GMM was
calculated by the following equation:
?GMM = ?Gintele +?Gintvdw ,
where ?Gintele  and ?Gintvdw  are electrostatic and van der Waals interaction energies
between a ligand and a protein. These energies were computed using the same
parameter set as that used in the MD simulation, and no cutoff was applied for the
calculation. Solvation energy ?Gsol  can be divided into two parts:
?Gsol = ?Gsolele +?Gsolnonpol .
The electrostatic contribution to the solvation free energy (?Gsolele ) was calculated by the
Poisson-Boltzmann (PB) method using the DelPhi program55. The hydrophobic
contribution to the solvation free energy (?Gsolnonpol ) was determined with a function of
the solvent-accessible surface-area56.
Hydrogen bond criterion. The formation of a hydrogen bond was defined in terms
of distance and orientation. The combination of donor D, hydrogen H, and acceptor A
atoms with a D - H … A configuration was regarded as a hydrogen bond when the
distance between donor D and acceptor A was shorter than Rmax(=3.5 Å) and the angle
H-D-A was smaller than ?max (=60.0˚).
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Results
  Binding energy calculations. The influence of L90M mutation on binding energy
?Gb  was examined for each ligand. Table 1 shows the results of MM/PBSA
calculations for the WT and L90M PR in complex with each ligand. L90M reduced the
binding energies of NFV and SQV. Results of some experiments have suggested that
L90M mutation caused resistance against these inhibitors7, 11-18. On the other hand,
L90M PR exhibits almost the same affinity as that of WT PR for LPV. It has been
reported that the affinity of LPV was hardly affected by any single mutations35. Hence,
the results of our simulations are compatible with the results of previous experimental
analyses. The affinity of L90M PR with PRRT is almost the same as that of WT PR.
Table 1. Binding energies of each model.
?Gintele ?Gintvdw ?Gsol ?Gb * ??Gb #
Resistant
Level†
WT -24.4±3.6 -66.6±3.6 37.5±3.3 -53.5±4.2NFV
L90M -20.2±3.8 -64.1±3.1 33.6±3.5 -50.7±4.6
+2.8 5
WT -29.6±4.7 -71.5±4.0 34.7±3.6 -66.4±5.2SQV
L90M -27.9±4.2 -72.9±3.8 37.1±3.6 -63.7±4.7
+2.7 3.5
WT -31.2±4.8 -71.1±3.7 41.0±3.4 -61.8±4.5LPV
L90M -29.8±5.2 -74.1±3.2 41.9±3.4 -62.1±4.9
-0.3 ~1
WT -74.7±9.3 -84.1±4.2 91.7±5.3 -67.2±7.5PRRT
L90M -72.4±6.3 -84.7±4.7 89.4±4.7 -67.7±5.4
-0.5 -
Energy is presented in units of kcal/mol.
* T?S is not included.
? ??Gb = ?Gb (L90M) ??Gb (WT)
† Resistance level was taken from references 7, 18, 35. Resistance level is defined as
IC90(L90M)/IC90(WT) or as IC50(L90M)/IC50(WT) in the references.
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  Hydrogen bonds between PR and ligands. Hydrogen bonds play an essential role in
stabilizing protein-ligand complexes. We examined 1000 snapshots during the last 500
ps and identified direct or one water molecule-mediated hydrogen bonds (Supporting
Information Table S2). NFV mainly creates hydrogen bonds with D25’ and D30 in the
WT model. In contrast, NFV interacts with D25 and D25’ in L90M PR. That is, NFV
hardly interacts with D30 in the L90M model. It is known that D30 contributes
significantly to PR-NFV binding and that the mutation D30N causes specific resistance
against NFV7, 14, 57, 58. Moreover, in WT and L90M PR, one water molecule is located
between I50/I50’ and NFV. This water molecule creates hydrogen bonds with I50’ of
WT PR (99.8% of the bonds being maintained during the last 500 ps of simulation) and
with I50 of L90M PR (92.4%), while these hydrogen bonds are often broken with NFV
in each model (~50%).  SQV has a direct interaction with D25’ and a one water
molecule-mediated interaction with I50’ in both WT and L90M models. In addition, the
main chain at the P2 subsite of SQV makes a hydrogen bond with G48 in both models.
In contrast, the side chain at the P2 subsite (-CONH2) interacts with different residues in
the two models. The side chain interacts with G48 in the WT model and with D30 in the
L90M model. Interestingly, G48 is a residue whose mutation causes specific resistance
against SQV15-18. Thus, both NFV and SQV lose significant hydrogen bonds due to
L90M mutation. On the other hand, LPV has similar hydrogen bond networks in the
WT and L90M models. LPV creates direct hydrogen bonds with D25, D25’, and D29.
One water molecule connects LPV to the 50th residues by hydrogen bonding. PRRT has
similar interactions with D29, D30, and G48 in S4-S1 pockets in the WT and L90M
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models. However, PRRT has different interactions in S1’-S4’ pockets. One water
molecule also stays between D25/D25’ and PRRT in the PR model, while it hardly
makes any stable hydrogen bond.
 Comparison of the structures of the WT and L90M models. In order to clarify the
effect of mutation at the 90th residue on active site conformation, the average structure
of the L90M model for the last 500 ps was compared with that of the corresponding WT
model. The L90M model was fitted to the WT model using the coordinates of the main
chain atoms N, C? and C, and the root mean squared deviation (RMSD) value was
calculated (Fig. 2). When the structures of each ligand in the WT and L90M models
were compared, some atoms of NFV and SQV were found to exhibit large RMSD
values (> 2.0 Å). Atoms at the thio-phenol group (-S-C6H5) in NFV are dislocated to a
quite different position, and all of the atoms in SQV are shifted in the same direction.
On the other hand, no atoms in LPV exhibit such large RMSD values. In the case of
PRRT, the P4-P1’ subsites have almost identical conformations, but there is a
prominent difference at the P2’-P4’ subsite. The tertiary structures of the WT PR and
L90M PR were also compared. RMSD 3D plots clearly indicate that deviation in the
NFV complex model is markedly large compared to other ligand-bound cases. In the
case of NFV, main chain atoms at the flap and at P79’ and its neighboring residues
show large differences in WT PR and L90M PR. We previously reported
conformational changes at the same residues33. There are small differences between the
results of the present study and those of the previous study regarding the residues at the
flap region. Namely, the flap region shows larger deviation from the WT in the present
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calculation. This is because the residues are flexible (Supporting Information Fig. S2)
and we examined larger sets of coordinates in this study (1000 sets of coordinates from
1.0-1.5 ns) than the previous study (200 sets of coordinates from 0.9-1.0 ns). L90M PR
in complex with SQV shows local conformational changes at P81 and its neighbors. In
the case of LPV, the main chain atoms at the active site are hardly affected by L90M
mutation, although some atoms at the non-active site show large deviations. In the case
of PRRT, the main chain atoms at I50’ and its neighbors show noticeable deviations.
15
Fig. 2. 3D plots of RMSD between the average structures of WT and L90M models. A:
Ligands in the L90M model are shown as colored sticks. B: PRs in the L90M model are
shown in colored tube representation, and D25/D25’ and I84/I84’ are shown in stick
representation. The color means the magnitude of RMSD shown in the bottom bar. The
L90M model was fitted on the WT model using the coordinates of main chain atoms N,
C? and C of PR. The superimposed gray sticks and tubes represent the structure of the
WT model.
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 Mechanism of conformational changes at the active site. Fig. 2 shows that L90M
mutation affects the location of the ligand and the tertiary conformation of the active
site of PR. In order to determine the reason for induction of these conformational
changes at the active site by the non-active site mutation L90M, conformations of the
catalytic triad D25T26G27 / D25’T26’G27’ have been examined in detail. These
residues have van der Waals contacts with the side chains of the 90th residues20, 26, 33 and
are located at the active site. In NFV, SQV, and PRRT complex models, some residues
showed about 1.0 Å deviations between WT and L90M PR (Supporting Information
Table S3). On the other hand, the deviations of all of these residues in the LPV complex
model are about 0.5 Å. These residues are the least fluctuating residues in PR because
they create rigid hydrogen bond networks, so-called fireman grips59 (Supporting
Information Fig. S2). The root mean squared fluctuations (RMSF) of these residues
were about 0.3 Å. Thus, these conformational changes at these triads are critically
important. In the case of NFV, SQV, and PRRT complex models, D25 C? -D25’ C?
distances are also different between the WT and L90M models (Table 2). There is a
particularly large difference in orientations of the side chains of D25/D25’. Furthermore,
in the case of NFV and SQV, rotations occur at the side chains of I84/I84’, which are
active site residues and are in contact with the side chains of D25/D25’ (Fig. 3). The
rotations are correlated with the changes in distances between D25 C? and I84 C? and
between D25’ C? and I84’ C?. That is, the rotations are induced by displacements of
the catalytic aspartates D25 and D25’.  The side chains of I84/I84’ have large
hydrophobic contacts with the ligands, and the structure of the active site is deformed
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asymmetrically. Consequently, we speculate that the following mechanism causes the
active site conformational changes. First, L90M mutation changes the interaction
between the 90th residues and D25/D25’. Second, D25/D25’ is shifted. Third, I84/I84’
show rotations of their side chains. Finally, the interaction between ligands and I84/I84’
causes conformational changes of the active site.
Table 2. Distances between D25 C?-D25’ C?,  D25 C?-I84 C?, and D25’ C?-I84’ C?.
D25C?-D25’C? NFV SQV LPV PRRT
WT 6.2±0.1 6.7±0.2 7.1±0.2 7.3±0.3
L90M 6.5±0.2 6.2±0.1 7.0±0.2 7.6±0.2
?? 0.3 -0.5 0.1 0.3
D25C?-I84C? NFV SQV LPV PRRT
WT 5.6±0.2 5.0±0.2 4.7±0.2 4.4±0.3
L90M 5.0±0.3 5.1±0.2 4.9±0.2 4.4±0.3
?? -0.6 0.1 0.2 0.0
D25’C?-I84’C? NFV SQV LPV PRRT
WT 4.4±0.2 5.4±0.4 5.2±0.2 5.0±0.2
L90M 5.8±0.3 5.8±0.2 5.2±0.2 5.1±0.2
?? 1.4 0.4 0.0 0.1
 Distances are presented in units of Å.
* Difference between L90M and WT.
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Fig. 3. Dihedral angles of N-C?-C?-C?1 of I84 (upper) and I84’ (lower) during the last
500 ps of simulations. Red lines represent the WT model, and green lines represent the
L90M model.
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Discussion
In HIV-1 PR, the 90th residue is located at the dimer interface, that is, out of
the substrate-binding pocket. Hence, it has no direct contact with any ligand of PR. In
spite of its location, L90M mutation causes resistance against FDA-approved PIs, such
as NFV and SQV7, 11-18. It is difficult to imagine the mechanism of resistance due to
L90M mutation. Several X-ray crystal structures have ever been provided for L90M
PR20-22, 26. These structures showed that the side chains of the mutated M90/M90’ altered
the interactions with the catalytic aspartates D25/D25’. Hong et al. determined the
crystal structure of G48V/L90M HIV-1 PR in complex with SQV. They proposed that
alteration in the interactions between the 90th residues and D25/D25’ led to reduction of
structural flexibility at the main chains of the catalytic triads and lowered the possibility
of these main chains making structural adjustments to SQV20. Mahalingam et al.
determined the structure of L90M HIV-1 PR in complex with IDV and with substrate
analogue inhibitors. They further analyzed kinetic characteristics of L90M mutants and
reported that L90M appeared to indirectly lower the dimer stability21, 22, 26. Our recent
study in which computational simulations of HIV-1 PR in complex with NFV were
carried out suggested that L90M mutation caused a decrease of binding energies and
that conformational changes appeared at the flap and 80’s loop regions, which are
distant from the 90th residues33. Hence, for NFV, we concluded that the drug resistance
due to L90M was caused by these active site conformational changes. In spite of the
accumulation of these experimental and theoretical findings, there has been no clear
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suggestion for drug designs to reduce the degree of or prevent the drug resistance due to
L90M.
In this study, investigations of L90M PR were carried out for the purpose of
establishing a strategy for promising drug design, and the structures of L90M PR in
complexes with NFV, SQV, LPV, and a substrate at the PR/RT cleavage site (PRRT)
were analyzed in detail. NFV and SQV lose their inhibitory efficacy for L90M
mutation7, 14-18. In contrast, LPV hardly changes its affinity with PR in spite of the L90M
mutation35. The substrate PRRT has a unique sequence, Phe-Pro, at P1/P1’ subunits,
whose structure is the basis for the drug design for NFV, SQV and other PIs3, 42. In all
computed models, changes in interaction between catalytic aspartates D25/D25’ and the
90th residues occur due to the L90M mutation. In contrast, different responses have
been observed at the active site of PR in the models. In the L90M PR / NFV complex,
L90M causes large conformational changes at the active site, especially at the flap and
80’s loop regions of PR. The L90M mutation also causes dislocations of side chains of
D25/D25’ and rotations of side chains of I84/I84’. In the L90M PR /SQV complex, a
positional shift of SQV and local conformational change at 80’s loop regions occur.
Dislocations of the side chains of D25/D25’ and rotations of I84/I84’ also occur, as in
the L90M PR / NFV complex. These conformational changes have also been observed
in the crystal structure of G48V/L90M PR / SQV complex (PDB code: 1FB720) when
compared with WT PR / SQV complex (PDB code: 1HXB42, 49). In addition, a
comparison of the structure of L90M PR in complex with SQV and the crystal structure
of G48V/L90M PR / SQV complex shows that the 80’s loop, where L90M causes
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conformational changes, is located at similar positions in the two structures (Supporting
Information Fig. S3). In the complex with each of these two inhibitors, L90M mutation
induces common effects: dislocations of the 25th residues and rotations of the side
chains of the 84th residues. In addition, L90M PR decreases the binding energy with
each of NFV and SQV, which would reflect the positional shift of the inhibitors. In
contrast, in the L90M PR / LPV complex, conformational changes hardly occur at the
active site. Dislocations of the 25th residues and rotations of the side chains of the 84th
residues hardly appear. Energetically, LPV exhibits the same binding affinity with
L90M and WT PRs. PRRT also exhibits the same affinity with L90M and WT PRs,
although conformations at both of the residues near I50/I50’ and P2’-P4’ subunits of
PRRT are greatly changed. In the PRRT model, no rotation of the side chains of
84I/84’I occurs, while the distance between the two side chains of D25 and D25’ is
changed. These results indicate that rotations of the side chains of I84/I84’ are involved
in the resistance due to L90M. Consequently, we can conclude that the mechanism of
resistance due to L90M is rotations of the side chains of the 84th residues due to
dislocations of the side chains of the 25th residues, which are initiated by changes in the
interactions between the 90th and the 25th residues. These rotations change the shapes
of the active sites, and the change decreases the interactions between PR and ligands
(Fig. 4). There is still the question of why rotation of the 84th side chains occurs when
L90M PR is bound with NFV or SQV but does not occur when L90M PR is bound with
LPV and PRRT. The answer to this question is that the rotations is due to not only to
dislocations of side chains of D25 / D25’ but also to the geometry of the ligand. The
22
shift in side chains of 25D/ 25’D occurs when L90M PR is bound with NFV, SQV, and
PRRT. Focusing on the P1/P1’ subsites of those ligands, NFV and SQV each contain a
dodecahydroisoquinoline ring, which is a rigid and bulky functional group, and PRRT
has a ring of PRO. These rings are located near D25/D25’ and assist the dislocation of
the side chains of D25/D25’ because of their rigidity. Moreover, the size of the rings is
responsible for the rotation of the side chains of I84/I84’. Rotation of the side chains of
the 84th residues occurs when L90M PR is bound with NFV or SQV. In contrast,
rotation hardly occurs in spite of the side chain dislocations of D25/D25’ when L90M
PR is bound with PRRT. The ring size of PRRT is smaller than those of NFV and SQV
and makes no unfavorable collision with side chains of I84/I84’. Consequently, the size
and flexibility of P1/P1’ subsites of the ligand are closely related to the resistance due to
L90M. We speculate that a single L90M mutation has little effect on the binding affinity
with a ligand that has a linear group or a small ring at its P1/P1’ subsite.
We further investigated the interactions between the ligands and each amino
acid residue of PRs by performing fragment molecular orbital (FMO) calculations60. In
the FMO scheme, the total system is divided into fragments and calculations are carried
out in parallel, which makes it possible to adopt the ab initio MO calculation for a large
molecule like a protein. The single point energy of each model was calculated at the
FMO-HF/6-31G level using the ABINIT-MP program61. The model structures were
constructed by the following two steps. First, the average structure was calculated on
the basis of 1000 coordinates acquired during the last 500 ps of MD simulation. Next,
energy minimization was executed on the average structure. One amino acid residue or
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one inhibitor was set as a single fragment. It was confirmed from the computational
results shown in Fig. 5 that each of the ligands indeed interacts with the active site
residues or their neighboring residues. Notably, LPV and PRRT interact with only
several active site residues. That is, the residues they interact with are quite limited
compared with those with which NFV and SQV interact. Furthermore, LPV shows no
significant difference between its interactions in WT and L90M PRs. LPV has highly
specific interactions with D29 and D25’, whose mutations inactivate the function of the
PR2, 62. Fig. 5 also indicates that NFV and SQV show noticeable loss of interaction
energies with several residues in both the WT and L90M models. In particular, NFV has
unfavorable contact with K45, R87, R8’, D29’, and D30’, and SQV has unfavorable
contact with D25’ and D29’. In contrast, LPV shows little energetical loss in the
interaction with protein residues in both models. Accordingly, we speculate that this
specificity and the little energetical loss are also reasons why L90M mutation has little
effect on the binding of LPV.
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Fig. 4. Structure around the active site. Each PR in the L90M model is shown in green
cartoon, and each of the ligands and important residues is shown in green ball and stick
representation. The superimposed gray cartoons and sticks represent the structure of the
WT model.
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Fig. 5. Inter-residue interaction energies between PR and ligand calculated by FMO-
HF/6-31G.  Black lines below indicate the location of the active site residues (R8,
L23-V32, I47-I50, P81-I84, R8’, L23’-V32’, I47’-I50’, P81’-I84’).
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Lastly, we investigated whether simulations can provide the correct order in
terms of potency of the inhibitors. In the comparison of ?G, the calculated inhibitory
order for NFV, SQV, and LPV is not compatible with that determined by experiments63
(Supporting Information Table S4). In contrast, when compared with experimental ?H,
the order in calculated ?G for the inhibitors is consistent with the experimental
measurements. That is because our MM/PBSA calculations do not include entropic
terms. Hence, the incorporation of an entropic term will enable us to accurately predict
the potency of a new drug by MD simulations.
LPV is one of the most promising drugs for AIDS treatment as shown in the
present study. However, as the number of mutations increases, the efficacy of LPV
decreases. For example, according to Virologic phenotypic assays, patient-derived HIV-
1 confers 20-fold resistance against LPV. The PR sequence of this HIV-1 includes some
drug resistant-related mutations (L10I, K20R, M36I, R41K, M46I, F53L, Q61N, L63P,
A71V, T74S, V82T, N88S, L90M, I93L). Results of our additional simulation of this
resistant PR with LPV have indicated a decrease in inhibitory efficacy (?Gb  = -59.5
kcal/mol, ??Gb  = +2.3 kcal/mol) (Supporting Information Fig. S4). These mutations
decrease the number of hydrogen bonds between LPV and this clinically derived PR
(Supporting Information Table S5). Furthermore, the mutations change the
conformations at the flap and 80’s loop regions (Supporting Information Fig. S5). A
design to remove the collisions at these regions will further enhance the efficacy of LPV.
It should be emphasized that most of the mutated residues are located at the non-active
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site of PR. Thus, in order to create more potent drugs, it is important to clarify the roles
of the drug-resistant related non-active site residues.
Based on the findings obtained in this study, we suggest the following
strategy for the design of HIV-1 PR inhibitors. First, inhibitors should not contain a
large ring such as a dodecahydroisoquinoline ring at P1/P1’ subsites; a linear chemical
group is favorable. Second, in order to remove the collisions at the 80’s loop and the
flap region, functional groups at P2P1/P1’P2’ subsites of inhibitors should be in the
same size as those of PRRT. Third, inhibitors should interact only with limited PR
residues such as D25/D25’ and D29/D29’. Finally, inhibitors should not make
unnecessary contact with any residues even in WT PR.
In summary, the mechanism of resistance due to the non-active site mutation
L90M has been clarified through theoretical calculations. The 90th residue of HIV-1 PR
is located at the dimer interface and has no direct contact with ligand chemicals. The
simulations demonstrate that the non-active site mutation affects conformation of the
binding cavity and ligand-binding affinity at the active site. The results of the present
study have revealed the drug resistance mechanism of non-active site mutation and
provide a clue for designing a promising drug to reduce the drug resistance due to non-
active site mutation. Adaptive drugs64-67, which have the ability to inhibit several
variants of a targeting enzyme, are needed in anti-HIV therapy. Some reviews have
suggested strategies for the design of adaptive inhibitors for HIV-1 PR64, 66-69. These
strategies, however, do not give sufficient consideration to the structural effects due to
28
non-active site mutations. The findings of this work should be useful for producing
practical adaptive drugs.
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